



Atty. Dkt. No. 065691/0149

RECEIVED
JUL 02 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Applicant: LORET *et al.*

Title: ANTI-RETROVIRAL FUNCTIONALIZED AROMATIC
COMPOUNDS

Appl. No.: 09/622,645

Filing Date: September 8, 2000

Examiner: F. Higel

Art Unit: 1626

18/B
Dmt
7-19-02

REPLY UNDER 37 C.F.R. § 1.121

Commissioner for Patents
Washington, D.C. 20231

Sir:

This communication is responsive to the Notice of Non-Compliant Amendment
dated May 28, 2002.

IN THE SPECIFICATION

At page 6, between paragraphs 4 and 5, please insert:

RECEIVED

JUL 02 2002

TECH CENTER 1600/2900

Brief Description of the Drawings

The present invention will be illustrated with no limitation being implied by the following examples with reference to Figures 1 to 7.

Figure 1 represents the HPLC profiles of TDS1, of Tat Bru, Tat Oyi and TDS1/Tat Bru and TDS1/Tat Oyi mixtures.

Figure 1A represents the HPLC profile of TDS1 at a concentration of 0.1 mM.

Figure 1B represents the HPLC profile of the Tat Bru protein at a concentration of 0.1 mM.

Figure 1C represents the HPLC profile of the TDS1 mixture with Tat Bru.

Figure 1D represents the HPLC profile of the crude product of synthesis of Tat Oyi.

Figure 1E represents the HPLC profile of the mixture of the crude product of synthesis of Tat Oyi with 0.1 mM TDS1.

Figure 1F represents the HPLC profile of the mixture of the crude product of synthesis of Tat Oyi with 1 mM TDS1.

Figures 2A, 2B and 2C represent the mass spectra of three fractions collected after HPLC from the crude product of synthesis of Tat Oyi. Figure 2B corresponds to the mass spectrum of the major peak present in Figure 1D, but which has disappeared in Figures 1E and 1F.

Figure 3A represents the LTR-Lac Z activity of human cells infested with the LTR of HIV-1 and a LacZ reporter gene encoding beta-Galactosidase in the presence of Tat Bru and TDS1.

Figure 3B shows the results of an experiment similar to that presented in Figure 3A where the reporter gene is replaced by *luc*, encoding luciferase.

Figure 4A represents the survival of MT4 cells in the presence of HIV-1 III B as a function of the concentration of TDS1, of the concentration of AZT and of the concentration of ddC.

Figure 4B represents the activity of reverse transcriptase at room temperature in the presence of HIV-1 III B as a function of the concentration of TDS1 and of the concentration of AZT.

Figure 5A represents the electrophoresis profiles of TAR, of the Tat Bru/TAR complex and of the Tat/TAR/TDS1 mixture after having incubated the Tat Bru protein with TDS1 for 30 minutes before the addition of TAR.

Figure 5B represents the electrophoresis profiles of TAR, of the Tat Bru/TAR complex and of the Tat/TAR/TDS1 mixture after having incubated the Tat Bru protein with TAR before the addition of TDS1.

Figure 6A represents the electrophoresis profiles of TAR, of the Tat Mal/TAR complex and of the Tat/TAR/TDS1 mixture after having incubated the Tat Mal protein with TDS1 for 30 minutes before the addition of TAR.

Figure 6B represents the electrophoresis profiles of TAR, of the Tat Mal/TAR complex and of the Tat/TAR/TDS1 mixture after having incubated the Tat Mal protein with TAR before the addition of TDS1.

Figure 7 represents the fluorescence spectra of Tat Eli (curve 1), of the Tat Eli/TDS complex (curve 2) and of TDS1 (curve 3), after excitation at 295 nm.

Detailed Description of the Preferred Embodiments

Paragraph
At page 18, ¶¶ 7-10, lines 30-39 continuing on to page 20, ¶¶ 2-3, lines 1-14, delete the text in its entirety.

Respectfully submitted,

Date June 28, 2002

By

Phillip J. Antivola

*R.G. No.
38,819*

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5143
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

for /

Stephen B. Maebius
Registration No. 35,264